echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jichuan Pharmaceutical Pudilan Anti-inflammatory Oral Liquid will be withdrawn from Shandong Medical Insurance List

    Jichuan Pharmaceutical Pudilan Anti-inflammatory Oral Liquid will be withdrawn from Shandong Medical Insurance List

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 10th, Jichuan Pharmaceutical issued an announcement stating that according to the "Regarding the Province’s Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs List" issued by the Shandong Provincial Medical Security Bureau and the Shandong Provincial Department of Human Resources and Social Security “Notice on Transfer of Work in 2021”, its wholly-owned subsidiary Jichuan Pharmaceutical Group Co.


    The indications of Pudilan Anti-inflammatory Oral Liquid are: clearing away heat and toxins, reducing swelling and relieving the pharynx


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.